Cambridge Regulatory Services

Additive Orthopaedics, LLC | October 23, 2020

Additive Orthopaedics, LLC., the leader in 3D printed orthopaedic foot and ankle devices, announces a novel breakthrough in orthopaedic additive manufacturing with their ability to incorporate locking technology in all of their Patient Specific Implants. The patent pending technology can be incorporated in Additive Orthopaedics Patient Specific 3D Printed Plates and Patient Specific 3D Printed Bone Segments. According to Luciano Bertolotti, Director of Engineering for Additive Orthopaedics, &quo...

Business Insights, PHARMACY MARKET

businesswire | April 17, 2023

OM1, a leading real-world data, outcomes and technology company with a focus on chronic conditions, today launched PhenOM™, its artificial intelligence-powered platform for personalized medicine. Calibrated using OM1’s longitudinal health history datasets, PhenOM uses AI to identify unique digital phenotypes associated with conditions and outcomes and compare patients’ records to them to highlight risks and opportunities. PhenOM powers personalized healthcare insights at ...

Business Insights

Athira Pharma, Inc. | October 18, 2022

Athira Pharma, Inc. a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that following an unblinded interim efficacy and futility analysis, an independent data monitoring committee recommended continuation of the LIFT-AD study of fosgonimeton in patients with mild-to-moderate Alzheimer’s disease. The committee also determined that, with the additional enrollment of fewer than 150 patien...

Huateng Pharma | February 11, 2020

This year is an unusual year due to the infection of the Novel Coronavirus Pneumonia (NCP) epidemic. Hunan Huateng Pharmaceutical Co., Ltd. (hereinafter referred to as Huateng)， as a drug research and development company with rich experience in developing antiviral drugs, has attached close attention to this matter. Considering that there is no targeted medicine for novel coronavirus pneumonia (NCP) infection and that NCP virus is highly similar to SARS / Middle East Respiratory Syndrome (MERS) ...